A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

Q3 2025 Management View CEO Jerrell Shelton highlighted double-digit growth in both Life Sciences Services and Life Sciences Product segments, noting "revenue from our support of commercial cell and ...

Rarity PBC raises $4.6M seed financing to advance ADA-SCID gene therapy licensed from UCLA and developed by Dr. Donald Kohn.

CDMOs must now offer platform-based manufacturing, simplified tech transfers, AI-driven automation, and robust analytical services. Speed is also critical—traditional 18–24-month timelines are no ...

TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...

After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of science the second Trump administration wants to back: in vivo cell ...

The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

Founded in 2016 by Jérémie Laurent at the Saint-Louis Hospital in Paris, a prestigious hub for leading cell therapy research, Astraveus is committed to revolutionizing the development and ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasd ...